Committee Recommends Approval for Dermatitis Treatment Be Extended
June 28 2019 - 8:03AM
Dow Jones News
By Allison Prang
The European Medicines Agency's Committee for Medicinal Products
for Human Use is recommending that approval for an atopic
dermatitis treatment from Regeneron Pharmaceuticals Inc. and Sanofi
be extended, the companies said Friday.
The committee is recommending that the European Union approval
be extended to also include people with moderate-to-severe cases of
this type of dermatitis who are systemic therapy candidates and
between ages 12 and 17, the companies said.
They said they expect the European Commission's final decision
on the treatment's application should come in the coming
months.
Write to Allison Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
June 28, 2019 07:48 ET (11:48 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024